Clinical Trials
70 trialsAndroMETa-CRC
AbbVie
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
PARERE
Gruppo Oncologico del Nord-Ovest
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
BBOpCo
Duke University
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
NIPAVect
Emory University
VICTORIA
National Cancer Institute, Naples
TRIFLUOX-DP
UNICANCER
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
SAMCO
Federation Francophone de Cancerologie Digestive
OPTIPRIME
Federation Francophone de Cancerologie Digestive
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
PANIRINOX
UNICANCER
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
VOLFI
AIO-Studien-gGmbH
PanaMa
AIO-Studien-gGmbH
PACER
National Cancer Institute, Naples
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
CHRONOS
Fondazione del Piemonte per l'Oncologia
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto
IMPROVE
National Cancer Institute, Naples
REPAN
King Abdullah Medical City
PIMABI
GERCOR - Multidisciplinary Oncology Cooperative Group
OPALO
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Amgen
SAPPHIRE
Takeda
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich
A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases
University Health Network, Toronto
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
PULSE
Grupo Espanol Multidisciplinario del Cancer Digestivo
ULTRA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Massachusetts General Hospital
BOS2
European Organisation for Research and Treatment of Cancer - EORTC
Valentino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
STEPP
Amgen
PRECEPT
Amgen